Dan Mendelson is CEO of Avalere Health, an advisory services company whose core purpose is to create innovative solutions to complex healthcare problems. Based in Washington DC, the firm delivers research, analysis, insight, and strategy for leaders in healthcare business and policy. Avalere’s experts span 130 staff drawn from the federal government (e.g., CMS, OMB, CBO, and the Congress), Fortune 500 healthcare companies, top consultancies, and nonprofits.


Prior to founding Avalere in 2000 Mendelson served as Associate Director for Health at the White House Office of Management and Budget under President Clinton. Before joining OMB, Mendelson was Senior Vice President of The Lewin Group and Director of the Medical Technology Practice.


Recent Posts by Dan Mendelson

The Ryan Plan And The Medicare Debate: The Crucial Questions

While Representative Paul Ryan’s (R-WI) most recent Medicare premium support proposal will be hotly debated during this charged political season, the more durable issue is what it means for the real debate on Medicare that looms after the election.  Regardless of who wins this November, the...

Establishing Sensible Cost-Sharing For Medicare Cancer Patients

A new study by Avalere Health, presented at the recent meeting of the American Society of Clinical Oncology, analyzed the pharmacy claims of 10,508 commercially-insured and Medicare patients who required oral therapy for cancer. The purpose of the study was to assess the effects of cost-sharing...

Look Carefully: Medicare’s Provenge National Coverage Decision

Editor’s Note: The authors of the post below, Dan Mendelson and Tanisha Carino, also wrote an earlier post on the initial decision of the Centers for Medicare and Medicaid Services to undertake a national coverage review of the cancer drug Provenge. In one of its most anticipated national...

Thoughtful Purchasing At CMS

Recent press reports on Medicare’s decision to evaluate coverage policy for the new cancer therapy Provenge were highly critical of the Centers for Medicare and Medicaid Services (CMS) and its role in examining the evidence behind FDA-approved products.  Let’s take a step back. In fact, this is...

Reform Starts Now: More Choice For Medicare’s Low-Income Rx Beneficiaries

An oft-heard criticism of the new health care law is that its major provisions do not kick in until 2014, leaving little immediate benefit for most Americans, especially those struggling in this economy. However, the reality is that the Affordable Care Act is already helping millions of...